Matthew Bolton, MD
Ophthalmology · New Orleans, LANPI 1992199129
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Alcon at 26.8% of the total. Reporting peaked in 2024 at $1,329 and has fallen 57.0% since, to $571 in 2025.
Across 154 payments — averaging $34.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Johnson & Johnson Surgical Vision, Inc.$785
- AbbVie$572
- Carl Zeiss Meditec USA, Inc.$464
- Ivantis, Inc$452
- Oyster Point Pharma, Inc.$370
- plus $1K from 20 others
What the payments were for
- Food & beverage$5,388100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 50 | $1,443 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $785 |
| AbbVie(2 entities) | 22 | $572 |
| Carl Zeiss Meditec USA, Inc. | 4 | $464 |
| Ivantis, Inc | 7 | $452 |
| Oyster Point Pharma, Inc. | 13 | $370 |
| Biotissue Holdings Inc. | 7 | $213 |
| Novartis | 5 | $186 |
| Aerie Pharmaceuticals, Inc. | 7 | $161 |
| Eyevance Pharmaceuticals LLC | 5 | $97 |
| Glaukos Corporation | 1 | $69 |
| Nova Eye, Inc. | 1 | $68 |
| Sun Pharmaceutical Industries Inc. | 3 | $65 |
| Mallinckrodt Hospital Products Inc. | 2 | $61 |
| Dompe US, Inc. | 2 | $56 |
| Harrow Eye, LLC | 2 | $53 |
| Bausch & Lomb Americas Inc. | 3 | $49 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $38 |
| Sight Sciences, Inc. | 1 | $32 |
| Thea Pharma Inc. | 2 | $31 |
| Merz Pharmaceuticals, LLC | 1 | $24 |
| NEW World Medical,inc. | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Tarsus Pharmaceuticals, Inc. | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $19 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$498
- Hydrus Microstent$384
- Clareon$262
- IOLMaster 700$196
- Hydrus$152
- CIRRUS HD-OCT$148
- DURYSTA$141
- Clareon PanOptix Pro$138
- ReSTOR$137
- Tecnis Simplicity$125
- Prokera$111
- AmnioGraft$111
- DUREZOL$111
How this compares
$5,388 in reported general payments places this provider in the 80th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 99 | $106,274 |
| RocklatanNetarsudil Mesylat/Latanoprost | 93 | $37,868 |
| LumiganBimatoprost | 36 | $17,938 |
| Prednisolone Acetate | 244 | $9,984 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $9,835 |
| VyzultaLatanoprostene Bunod | 15 | $6,942 |
| Ketorolac Tromethamine | 173 | $4,147 |
| Latanoprost | 523 | $3,728 |
| Travoprost | 29 | $2,917 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 186 | $2,036 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 35 | $1,847 |
| Timolol Maleate | 153 | $1,743 |
| Ofloxacin | 113 | $1,291 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $1,045 |
| ErythromycinErythromycin Base | 69 | $858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $572 | $134,048153 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $161 | $37,86893 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $49 | $6,94215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in New Orleans
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
- Peter KastlNew Orleans$32K
- Benjamin LeeNew Orleans$7K
- Glen CangelosiNew Orleans$6K
- Barry LeaderNew Orleans$5K
- Blake WilliamsonBaton Rouge$443K
- Wyche ColemanShreveport$35K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.